Loteprednol Online



How and where to order Loteprednol (Lotemax) 0.5% 5 ml eye drops online:

Shop:CHEAP MEDS FOR SALE
Prices:from $12.99 per bottle
Discount:5% coupon: 5OFF
Forms:Loteprednol Etabonate (Lotemax) 0.5% 5 ml ophthalmic solution
Quantity:1-6 bottles
Type:Loteprednol brand, Lotemax generic
Payment:Visa, MasterCard, AmEx, Bitcoin
Delivery:Standard airmail and trackable courier service
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia


Loteprednol (trade names include Lotemax, Alrex, Loteflam, Lotepred, Loteprol, Lotesoft, Oftol Forte) is an ophthalmological antiinflammatory medication from corticosteroids pharmacological group. This medicine is used for the treatment of swelling and redness caused by certain eye conditions or surgery. Ocular applications for Loteprednol include the therapy of inflammation of the eye due to allergies, as well as chronic forms of keratitis (such as adenoviral and Thygeson's keratitis), pingueculitis, vernal keratoconjunctivitis, and episcleritis. Lotemax eye drops has little or no effect on intraocular pressure.

Lotemax (Loteprednol)

Related medications:

  • Alclometasone (Modrasone)
  • Atropine (Atropisol)
  • Azelastine (Optivar)
  • Betamethasone (Sanbeta)
  • Betaxolol (Kerlone)
  • Bimatoprost (Latisse, Lumigan)
  • Brimonidine (Alphagan)
  • Ciprofloxacin (Ciloxan)
  • Clobetasone (Visucloben)
  • Cortisone (Cortone)
  • Cyclopentolate (Cyclogyl)
  • Cyclosporine (Cyclomune)
  • Desonide (Prenacid)
  • Dexamethasone (Maxidex)
  • Dorzolamide, Timolol Maleate (Cosopt)
  • Fluocinolone Acetonide (Dermotic)
  • Fluorometholone (Fluforte)
  • Formocortal (Formoftil)
  • Hydrocortisone (Ficortril)
  • Latanoprost (Xalatan)
  • Levobunolol (Betagan)
  • Medrysone (HMS)
  • Ofloxacin (Ocuflox)
  • Prednisolone (Predone)
  • Rimexolone (Vexol)
  • Timolol (Timoptic)
  • Tobramycin (Tobrex)
  • Travoprost (Travatan)
  • Triamcinolone (Kenalog)
  • Unoprostone Isopropyl (Rescula)


    Pharmacological and medical categories:

  • Antiinflammatory drugs
  • Eye care medications
  • Eye corticosteroids
  • Glucocorticoids
  • Ophthalmological medications


    ATC codes:

  • S - Sensory organs
  • S01 - Ophthalmologicals
  • S01B - Antiinflammatory agents
  • S01BA - Corticosteroids, plain
  • S01BA14 - Loteprednol


    ICD-10 codes:

  • Other inflammation of eyelid - H01
  • Conjunctivitis - H10
  • Pingueculitis - H10.81
  • Disorders of sclera - H15
  • Keratitis - H16
  • Vernal keratoconjunctivitis, with limbar and corneal involvement - H16.26
  • Other specified disorders of eye and adnexa - H57.8


    Indications and usage:

    Lotemax (Loteprednol Etabonate) eye drops are indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.

    Lotemax is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with Loteprednol experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP ( >= 10 mmHg) was 1% with Lotemax and 6% with prednisolone acetate 1%. This medication should not be used in patients who require a more potent corticosteroid for this indication.

    Loteprednol is also indicated for the treatment of post-operative inflammation following ocular surgery.


    Contraindications:

    Lotemax (Loteprednol Etabonate) ophthalmic solution, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Lotemax is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.


    Dosage and administration:

    Shake vigorously before using Lotemax (Loteprednol) eye drops.

    Steroid Responsive Disease Treatment

    Apply one to two drops of Lotemax into the conjunctival sac of the affected eye four times daily. During the initial treatment within the first week, the dosing may be increased, up to 1 drop every hour, if necessary. Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after two days, the patient should be re-evaluated.

    Post-Operative Inflammation

    Apply one to two drops of Lotemax into the conjunctival sac of the operated eye four times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the post-operative period.


    Dosage forms and strengths:

    Lotemax contains 5 mg/g of loteprednol etabonate, as a sterile preserved ophthalmic gel, ointment or suspension.


    Warnings and precautions:

  • Intraocular pressure (IOP) increase - prolonged use of corticosteroids, including loteprednol may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored.
  • Cataracts - use of corticosteroids may result in posterior subcapsular cataract formation.
  • Delayed healing the use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.
  • Bacterial infections prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infection. In acute purulent conditions, steroids may mask infection or enhance existing infection.
  • Viral infections employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).
  • Fungal infections fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use.


    Information for Patients

    This product is sterile when packaged. Patients should be advised not to allow the dropper tip to touch any surface, as this may contaminate the suspension. If pain develops, redness, itching or inflammation becomes aggravated, the patient should be advised to consult a physician. As with all ophthalmic preparations containing benzalkonium chloride, patients should be advised not to wear soft contact lenses when using Lotemax (Loteprednol).


    Adverse reactions, side effects:

    Reactions associated with ophthalmic steroids such as Loteprednol include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.

    Ocular adverse reactions occurring in 5%-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2%-0.5%) in clinical studies included abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia. Other ocular adverse reactions occurring in less than 5% of patients include conjunctivitis, corneal abnormalities, eyelid erythema, keratoconjunctivitis, ocular irritation/pain/discomfort, papillae, and uveitis. Some of these events were similar to the underlying ocular disease being studied.

    Non-ocular adverse reactions occurred in less than 15% of patients. These include headache, rhinitis and pharyngitis.


    Use in specific populations:

    Pregnancy

    Teratogenic effects: Loteprednol etabonate has been shown to be embryotoxic (delayed ossification) and teratogenic (increased incidence of meningocele, abnormal left common carotid artery, and limb flexures) when administered orally to rabbits during organogenesis at a dose of 3 mg/kg/day (35 times the maximum daily clinical dose), a dose which caused no maternal toxicity. The no-observed-effect-level (NOEL) for these effects was 0.5 mg/kg/day (6 times the maximum daily clinical dose). Oral treatment of rats during organogenesis resulted in teratogenicity (absent innominate artery at >= 5 mg/kg/day doses, and cleft palate and umbilical hernia at >= 50 mg/kg/day) and embryotoxicity (increased post-implantation losses at 100 mg/kg/day and decreased fetal body weight and skeletal ossification with >= 50 mg/kg/day). Treatment of rats with 0.5 mg/kg/day (6 times the maximum clinical dose) during organogenesis did not result in any reproductive toxicity. Loteprednol etabonate was maternally toxic (significantly reduced body weight gain during treatment) when administered to pregnant rats during organogenesis at doses of >= 5 mg/kg/day.

    Oral exposure of female rats to 50 mg/kg/day of loteprednol etabonate from the start of the fetal period through the end of lactation, a maternally toxic treatment regimen (significantly decreased body weight gain), gave rise to decreased growth and survival, and retarded development in the offspring during lactation; the NOEL for these effects was 5 mg/kg/day. Loteprednol etabonate had no effect on the duration of gestation or parturition when administered orally to pregnant rats at doses up to 50 mg/kg/day during the fetal period. There are no adequate and well controlled studies in pregnant women. Lotemax should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Nursing mothers

    It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemic steroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Caution should be exercised when Lotemax is administered to a nursing woman.

    Pediatric use

    Safety and effectiveness in pediatric patients have not been established.

    Geriatric use

    No overall differences in safety and effectiveness have been observed between elderly and younger patients.


    Pregnancy categories:

  • C - Australia
  • C - United States (Risk cannot be ruled out)


    Salts and other forms:

  • Loteprednol Base
  • Loteprednol Etabonate


    Synonyms, international and chemical names:

  • Loteprednol Etabonato
  • Loteprednole
  • Loteprednoli
  • Loteprednolo
  • Loteprednolum


    Brands, generics, trade names:

  • Alrex - Bausch and Lomb
  • Loteflam - Cipla
  • Lotemax - Bausch and Lomb
  • Lotepred - Sun Pharmaceutical Industries
  • Lotepred-LS - Sun Pharmaceutical Industries
  • Loteprol - Bausch and Lomb
  • Loterex - Bausch and Lomb
  • Lotesoft - Poen Laboratorios
  • Oftol - Saval Laboratorios
  • Oftol Forte - Saval Laboratorios


    APIs used in medicine in combinations with loteprednol:

  • Gatifloxacin
  • Moxifloxacin
  • Tobramycin


    Here is a list of popular medications containing loteprednol etabonate as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

    Trade name of the drug Pharmaceutical forms and doses Companies
    Alrex
  • Suspension; Ophthalmic; Loteprednol Etabonate 0.2%
  • Bausch and Lomb
  • Firma Chun Cheong
  • U.S. Summit
  • Loteflam
  • Drops; Ophthalmic; Loteprednol Etabonate 0.5%
  • Cipla
  • Lotemax
  • Gel; Ophthalmic; Loteprednol Etabonate 0.5%
  • Ointment; Ophthalmic; Loteprednol Etabonate 0.5%
  • Suspension; Ophthalmic; Loteprednol Etabonate 0.5%
  • Bausch and Lomb
  • DKSH
  • Firma Chun Cheong
  • Hyphens Pharma
  • Invida
  • U.S. Summit
  • Zuellig Pharma
  • Lotepred
  • Drops; Ophthalmic; Loteprednol Etabonate 0.5%
  • Sun Pharmaceutical Industries
  • Loteprol
  • Suspension; Ophthalmic; Loteprednol Etabonate 0.5%
  • Bausch and Lomb
  • Lotesoft
  • Suspension; Ophthalmic; Loteprednol Etabonate 0.5%
  • Poen Laboratorios
  • Oftol Forte
  • Suspension; Ophthalmic; Loteprednol Etabonate 0.5%
  • Saval Laboratorios



  • References:

  • Loteprednol main article on Wikipedia: https://en.wikipedia.org/wiki/Loteprednol
  • Loteprednol compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Loteprednol
  • Loteprednol Etabonate compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Loteprednol-etabonate
  • Loteprednol on DrugBank: https://www.drugbank.ca/drugs/DB00873
  • Loteprednol Etabonate on DrugBank: https://www.drugbank.ca/drugs/DB14596
  • Loteprednol Ophthalmic FAQ on MedlinePlus (revised 12/15/2020): https://medlineplus.gov/druginfo/meds/a619025.html
  • Lotemax (Loteprednol Etabonate) ophthalmic suspension / eye drops drug label info on DailyMed (revised April 5, 2010): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
  • Lotemax (Loteprednol Etabonate) ophthalmic gel drug label info on DailyMed (revised April 30, 2020): https://dailymed.nlm.nih.gov/dailymed/lookup...
  • Loteprednol for sale on Pharma Doctor: https://pharma-doctor.com/loteprednol.html
  • Loteprednol containing drugs on Drugs-About.com: https://drugs-about.com/ing/loteprednol.html
  • Lotemax (Loteprednol Etabonate) ophthalmic gel 0.5% official prescribing and patient counseling information from the U.S. FDA (revised 09/2012): https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Lotemax SM (Loteprednol Etabonate) ophthalmic gel 0.38% official prescribing and patient counseling information from the U.S. FDA (revised 02/2019): https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Lotemax (Loteprednol Etabonate) ophthalmic ointment 0.5% official prescribing and patient counseling information from the U.S. FDA (revised 04/2011): https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Lotemax (Loteprednol Etabonate) ophthalmic suspension 0.5% prescribing information from Bausch & Lomb pharmaceutical company (revised September 2016): https://www.bausch.com/Portals/69/-/m/BL/...
  • Lotemax (Loteprednol Etabonate) ophthalmic gel 0.5% official website: https://www.lotemaxgel.com/
  • Lotemax (Loteprednol Etabonate) eye drops, suspension 0.5% package information leaflet Medicines.org.uk (revised February 2020): https://www.medicines.org.uk/emc/files/pil.6212.pdf
  • Loteflam (Loteprednol Etabonate, Lotemax generic) eye drops 0.5% prescribing information from Cipla pharmaceutical company (revised December 2018): https://www.ciplamed.com/content/loteflam-eye-drops

    Revised: April 2021



    Home | About Us | Services | Products | Contact

    Copyright © 2011 - 2021 Ophthalmic Used Equipment. All rights reserved.